TriangleTROP2-Directed CAR-NK (NCT07411599)
TROP2-Directed CAR-NK trial for Colorectal Cancer (NCT07411599). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for colorectal cancer that has spread to the peritoneum, the lining of the abdomen.
The idea: deliver immune cells two ways, by vein and directly into the abdomen. Natural killer cells are engineered to recognize TROP2 and to carry the signal IL-15, with the TGF-beta receptor 2 gene switched off. They are given with cetuximab, an antibody medicine, after chemotherapy that lowers existing lymphocytes.
First the study looks for the highest dose that can be given. Then it asks whether that dose can help control the disease. At MD Anderson in Houston, Paula Smith leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.